MedTrace Logo

Drug Interaction Study on Linaprazan Glurate Capsules

NCT07294846 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2026-01-06

No results posted yet for this study

Summary

This study is a drug-drug interaction (DDI) investigation involving Linaprazan Glurate capsules and a combination of clarithromycin tablets, amoxicillin capsules, and bismuth potassium citrate capsules. The study plan is divided into two parts: one involving Hp-negative healthy subjects and the other involving Hp-positive subjects.

Conditions

  • Healthy Volunteers
  • Patients

Interventions

DRUG

Linaprazan Glurate Capsules

Linaprazan Glurate capsules

DRUG

Bismuth Potassium Citrate Capsules

Bismuth Potassium Citrate Capsules

DRUG

Amoxicillin Capsules

Amoxicillin Capsules

DRUG

Clarithromycin tablets

Clarithromycin Tablets

DRUG

Esomeprazole Magnesium Enteric-coated Tablets

Esomeprazole Magnesium Enteric-coated Tablets

Sponsors & Collaborators

  • Jiangsu Sinorda Biomedicine Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Ming Lu · Shanghai Sinorda Biomedicine Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-08
Primary Completion
2025-12-15
Completion
2025-12-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07294846 on ClinicalTrials.gov